Literature DB >> 29624860

Hepatic encephalopathy: Diagnosis and management.

Piero Amodio1.   

Abstract

Hepatic encephalopathy (HE) is a peculiar kind of brain dysfunction caused by liver insufficiency and/or portal-systemic shunting. It is related to gut-derived substances. It is a relevant cause of morbidity and hospitalisation for patients with cirrhosis. The prognosis of HE is important in terms of survival and re-hospitalisation. It is related to impaired quality of life, falls and poor driving; presents a relevant burden for caregivers and health services; and may negatively impact on patient's job and income. Proper diagnosis and classification are expected to improve HE management. Once diagnosed, the management and therapeutic options for HE are generally clear. The improvement of knowledge in recent years has also clarified which are the further aims of research in this field of medicine. Prophylaxis of overt HE should always be performed, and this is generally secondary prophylaxis. Primary prophylaxis should be done immediately after upper gastrointestinal bleeding. Great advances in the detection and treatment of mild forms of HE are expected to lead to further improvement in patient management.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cirrhosis; delirium; hepatic encephalopathy; portal-systemic shunt

Mesh:

Year:  2018        PMID: 29624860     DOI: 10.1111/liv.13752

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  8 in total

1.  Liver Transplant Patients with High Preoperative Serum Bilirubin Levels Are at Increased Risk of Postoperative Delirium: A Retrospective Study.

Authors:  Kyu Hee Park; Hyo Jung Son; Yoon Ji Choi; Gene Hyun Park; Yoon Sook Lee; Ju Yeon Park; Hyun-Su Ri; Jae Ryong Shim
Journal:  J Clin Med       Date:  2020-05-24       Impact factor: 4.241

2.  Supplementation with Synbiotics and/or Branched Chain Amino Acids in Hepatic Encephalopathy: A Pilot Randomised Placebo-Controlled Clinical Study.

Authors:  Helen Vidot; Erin Cvejic; Liam J Finegan; E Arthur Shores; David G Bowen; Simone I Strasser; Geoffrey W McCaughan; Sharon Carey; Margaret Allman-Farinelli; Nicholas A Shackel
Journal:  Nutrients       Date:  2019-08-06       Impact factor: 5.717

Review 3.  Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis.

Authors:  Daniela Campion; Ilaria Giovo; Paola Ponzo; Giorgio M Saracco; Federico Balzola; Carlo Alessandria
Journal:  World J Hepatol       Date:  2019-06-27

Review 4.  Lights and Shadows in Hepatic Encephalopathy Diagnosis.

Authors:  Piero Amodio; Sara Montagnese
Journal:  J Clin Med       Date:  2021-01-18       Impact factor: 4.241

5.  Association between serum albumin and cognitive dysfunction in hepatic encephalopathy: An exploratory data analysis.

Authors:  Kosuke Kaji; Kiwamu Okita; Kazuyuki Suzuki; Ikuya Sato; Masaki Fujisawa; Hitoshi Yoshiji
Journal:  JGH Open       Date:  2020-12-07

6.  Application of Bone Marrow Mesenchymal Stem Cells Effectively Eliminates Endotoxemia to Protect Rat from Acute Liver Failure Induced by Thioacetamide.

Authors:  Ting Jiang; Geng Xia; Bo Yang; Hong-Wei Zhang; Yue-Shan Yin; Cheng-Wei Tang; Jin-Hui Yang
Journal:  Tissue Eng Regen Med       Date:  2022-02-05       Impact factor: 4.169

7.  Increased rate of enteric bacteria as cause of periprosthetic joint infections in patients with liver cirrhosis.

Authors:  Uta S Koepf; Sebastian Scheidt; Gunnar T R Hischebeth; Christian P Strassburg; Dieter C Wirtz; Thomas M Randau; Philipp Lutz
Journal:  BMC Infect Dis       Date:  2022-04-19       Impact factor: 3.667

8.  Brain magnetic resonance imaging radiomics features associated with hepatic encephalopathy in adult cirrhotic patients.

Authors:  Gianvincenzo Sparacia; Giuseppe Parla; Roberto Cannella; Giuseppe Mamone; Ioannis Petridis; Luigi Maruzzelli; Vincenzina Lo Re; Mona Shahriari; Alberto Iaia; Albert Comelli; Roberto Miraglia; Angelo Luca
Journal:  Neuroradiology       Date:  2022-04-30       Impact factor: 2.995

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.